The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression

The effectiveness of the esketamine nasal spray (ESK-NS) for treatment-resistant depression (TRD) has been confirmed by real-world studies. Available evidence derived from clinician-rated assessments might differ from patients’ perceptions about the helpfulness of treatments. We aimed to verify the...

Full description

Saved in:
Bibliographic Details
Published inBrain sciences Vol. 13; no. 10; p. 1494
Main Authors Pepe, Maria, Bartolucci, Giovanni, Marcelli, Ilaria, Pesaresi, Francesco, Brugnami, Andrea, Caso, Romina, Fischetti, Alessia, Grisoni, Flavia, Mazza, Marianna, Camardese, Giovanni, Di Nicola, Marco, Sani, Gabriele
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 01.10.2023
MDPI
Subjects
Antidepressants
Cognition
Cognition & reasoning
Depression, Mental
Drug therapy
glutamatergic system
Hedonic response
Mental depression
mood disorders
patient experience
Patients
personalized medicine
Phenotypes
Psychopathology
psychopharmacology
Respiratory agents
Suicide
Online AccessGet full text

Cover

Abstract The effectiveness of the esketamine nasal spray (ESK-NS) for treatment-resistant depression (TRD) has been confirmed by real-world studies. Available evidence derived from clinician-rated assessments might differ from patients’ perceptions about the helpfulness of treatments. We aimed to verify the effect of ESK-NS from patients’ view in 25 TRD patients (56% males, 55.1 ± 10.9 years) treated with ESK-NS (mean dose: 78.4 ± 11.43 mg) for three months and evaluated at different time-points through clinician-rated and self-administered scales, assessing changes in depression, anhedonia, sleep, cognition, suicidality, and anxiety. We observed an overall early improvement that lasted over time (endpoint total score reduction in Montgomery-Åsberg Depression Rating Scale, p < 0.001, Beck Depression Inventory, p = 0.003). Patients reported a significant self-rated decrease in anhedonia at two months (Snaith–Hamilton Pleasure Scale, p = 0.04) and in suicide ideation at endpoint (BDI subitem 9, p = 0.039) vs. earlier improvements detected by clinicians (one-month reduction in MADRS subitem 8, p = 0.005, and subitem 10, p = 0.007). These findings confirm the effectiveness of a three-month treatment with ESK-NS in TRD patients, highlighting an overall overlapping response from patients’ and clinicians’ perspectives, although with some differential effects on specific symptoms at given time-points. Including patients’ viewpoints in routine assessments could inform clinical practice, ensuring a better characterization of clinical phenotypes to deliver personalized interventions.
AbstractList The effectiveness of the esketamine nasal spray (ESK-NS) for treatment-resistant depression (TRD) has been confirmed by real-world studies. Available evidence derived from clinician-rated assessments might differ from patients’ perceptions about the helpfulness of treatments. We aimed to verify the effect of ESK-NS from patients’ view in 25 TRD patients (56% males, 55.1 ± 10.9 years) treated with ESK-NS (mean dose: 78.4 ± 11.43 mg) for three months and evaluated at different time-points through clinician-rated and self-administered scales, assessing changes in depression, anhedonia, sleep, cognition, suicidality, and anxiety. We observed an overall early improvement that lasted over time (endpoint total score reduction in Montgomery-Åsberg Depression Rating Scale, p < 0.001, Beck Depression Inventory, p = 0.003). Patients reported a significant self-rated decrease in anhedonia at two months (Snaith–Hamilton Pleasure Scale, p = 0.04) and in suicide ideation at endpoint (BDI subitem 9, p = 0.039) vs. earlier improvements detected by clinicians (one-month reduction in MADRS subitem 8, p = 0.005, and subitem 10, p = 0.007). These findings confirm the effectiveness of a three-month treatment with ESK-NS in TRD patients, highlighting an overall overlapping response from patients’ and clinicians’ perspectives, although with some differential effects on specific symptoms at given time-points. Including patients’ viewpoints in routine assessments could inform clinical practice, ensuring a better characterization of clinical phenotypes to deliver personalized interventions.
The effectiveness of the esketamine nasal spray (ESK-NS) for treatment-resistant depression (TRD) has been confirmed by real-world studies. Available evidence derived from clinician-rated assessments might differ from patients’ perceptions about the helpfulness of treatments. We aimed to verify the effect of ESK-NS from patients’ view in 25 TRD patients (56% males, 55.1 ± 10.9 years) treated with ESK-NS (mean dose: 78.4 ± 11.43 mg) for three months and evaluated at different time-points through clinician-rated and self-administered scales, assessing changes in depression, anhedonia, sleep, cognition, suicidality, and anxiety. We observed an overall early improvement that lasted over time (endpoint total score reduction in Montgomery-Åsberg Depression Rating Scale, p < 0.001, Beck Depression Inventory, p = 0.003). Patients reported a significant self-rated decrease in anhedonia at two months (Snaith–Hamilton Pleasure Scale, p = 0.04) and in suicide ideation at endpoint (BDI subitem 9, p = 0.039) vs. earlier improvements detected by clinicians (one-month reduction in MADRS subitem 8, p = 0.005, and subitem 10, p = 0.007). These findings confirm the effectiveness of a three-month treatment with ESK-NS in TRD patients, highlighting an overall overlapping response from patients’ and clinicians’ perspectives, although with some differential effects on specific symptoms at given time-points. Including patients’ viewpoints in routine assessments could inform clinical practice, ensuring a better characterization of clinical phenotypes to deliver personalized interventions.
Audience Academic
Author Brugnami, Andrea
Mazza, Marianna
Bartolucci, Giovanni
Marcelli, Ilaria
Camardese, Giovanni
Pepe, Maria
Pesaresi, Francesco
Fischetti, Alessia
Grisoni, Flavia
Sani, Gabriele
Caso, Romina
Di Nicola, Marco
AuthorAffiliation 1 Department of Neuroscience, Section of Psychiatry, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy
2 Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy
AuthorAffiliation_xml – name: 1 Department of Neuroscience, Section of Psychiatry, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy
– name: 2 Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy
Author_xml – sequence: 1
  fullname: Pepe, Maria
– sequence: 2
  fullname: Bartolucci, Giovanni
– sequence: 3
  fullname: Marcelli, Ilaria
– sequence: 4
  fullname: Pesaresi, Francesco
– sequence: 5
  fullname: Brugnami, Andrea
– sequence: 6
  fullname: Caso, Romina
– sequence: 7
  fullname: Fischetti, Alessia
– sequence: 8
  fullname: Grisoni, Flavia
– sequence: 9
  fullname: Mazza, Marianna
– sequence: 10
  fullname: Camardese, Giovanni
– sequence: 11
  fullname: Di Nicola, Marco
– sequence: 12
  fullname: Sani, Gabriele
BookMark eNptksFuEzEQhleoiJbSO8eVuHBJsdf22j6hqg0QqRIVCmfL9o5Th1072E4lbrwGr9cnqUMqIBX2waOZf77RWP_L5ijEAE3zGqNzQiR6Z5L2IVuPCUaYSvqsOekQ72eEduzon_i4Oct5jeoRCBGGXjTHhAuJRY9OGljeQnuji4dQ7n_-yu0NpLwBW_wdtDG0pZbnztVEbqNrF6EkHXTWYzvP36DoyQdofWiXCXSZKmT2BbLPRYfSXsEmQc4-hlfNc6fHDGeP72nz9cN8eflpdv354-Ly4npmGWFlJrhxkjLjDFDGBAhDetNh2RMKhjprGPQdIVY4KyWnFNFBa8GHYSDcYC3IabPYc4eo12qT_KTTDxW1V78TMa2UTsXbEZTTFFmOJBmspBw6aUFCV4ciAIOtqaz3e9ZmayYYLOxWHw-gh5Xgb9Uq3imMekQl6yvh7SMhxe9byEVNPlsYRx0gbrPqhCCM95R2VfrmiXQdtynUv9qpOoKJYPSvaqXrBj64WAfbHVRdcI4l7jAhVXX-H1W9A0zeVg85X_MHDWjfYFPMOYH7syRGamc19dRq5AHiCMm4
CitedBy_id crossref_primary_10_3389_fpsyt_2024_1415505
crossref_primary_10_1016_j_euroneuro_2024_04_014
crossref_primary_10_1016_j_jadr_2024_100779
Cites_doi 10.1016/S0033-3182(71)71479-0
10.1038/s41380-020-00878-1
10.1016/j.jad.2021.06.032
10.20944/preprints202306.0108.v1
10.1038/npp.2016.229
10.1037/bul0000305
10.1590/1806-9282.2023d694
10.1016/j.euroneuro.2023.04.011
10.1093/ijnp/pyab039
10.1016/j.pnpbp.2021.110289
10.1007/978-981-19-7376-5_21
10.1002/da.20505
10.1038/s41380-021-01381-x
10.1002/wps.21111
10.1111/bdi.13296
10.1016/j.jad.2022.09.043
10.1097/PRA.0000000000000723
10.1192/bjp.134.4.382
10.1037/t00742-000
10.1177/2040622315627805
10.1186/s12888-023-05017-y
10.2147/NDT.S401032
10.3390/brainsci13081223
10.3390/ph16040634
10.1016/j.neubiorev.2022.105000
10.1016/j.neuropharm.2022.109299
10.1097/YIC.0000000000000403
10.1186/s12888-023-05038-7
10.3390/neurolint15010009
10.1097/YIC.0000000000000378
10.1097/YIC.0000000000000488
10.9758/cpn.22.1034
10.1093/ijnp/pyab084
10.4088/JCP.20m13699
10.1176/appi.ajp.2020.20081251
10.1002/wps.20771
10.1016/j.comppsych.2010.04.011
10.1016/j.jpsychires.2022.12.024
10.1111/bjc.12335
10.1176/appi.books.9780890425787
10.1016/j.parkreldis.2009.02.004
10.2147/NDT.S314874
10.1016/S0924-9338(00)00229-7
10.1002/da.22968
10.1007/s10072-021-05845-4
10.1111/j.2044-8341.1959.tb00467.x
10.1002/da.22774
10.1007/s00406-023-01617-7
10.3390/ijms22179338
10.1016/j.psychres.2023.115378
10.1016/j.eclinm.2023.102084
10.1016/S2215-0366(20)30516-2
10.1007/s00213-023-06388-6
10.1016/j.jagp.2023.06.016
10.1111/ejn.14720
10.1017/S0033291721004943
10.1007/s00213-022-06105-9
10.1016/j.neubiorev.2023.105307
10.9758/cpn.23.1086
10.1177/02698811221104058
10.1016/j.jad.2020.09.056
10.1007/s11136-023-03451-9
10.1001/jamapsychiatry.2020.1107
10.1016/j.euroneuro.2020.01.001
10.1176/appi.ajp.2019.19020172
ContentType Journal Article
Copyright COPYRIGHT 2023 MDPI AG
2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2023 by the authors. 2023
Copyright_xml – notice: COPYRIGHT 2023 MDPI AG
– notice: 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2023 by the authors. 2023
DBID AAYXX
CITATION
3V.
7TK
7XB
8FE
8FH
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
COVID
DWQXO
GNUQQ
GUQSH
HCIFZ
LK8
M2O
M7P
MBDVC
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.3390/brainsci13101494
DatabaseName CrossRef
ProQuest Central (Corporate)
Neurosciences Abstracts
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
ProQuest Central Student
Research Library Prep
SciTech Premium Collection
Biological Sciences
Research Library
Biological Science Database
Research Library (Corporate)
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Research Library
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Coronavirus Research Database
Biological Science Database
ProQuest SciTech Collection
Neurosciences Abstracts
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database


MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 2076-3425
ExternalDocumentID oai_doaj_org_article_fa40c7093dc947e29ce9e258e0eeb1cb
A771912133
10_3390_brainsci13101494
GroupedDBID 3V.
53G
5VS
8FE
8FH
8G5
AADQD
AAFWJ
AAYXX
ABDBF
ABUWG
ADBBV
AFKRA
AFPKN
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
CITATION
DWQXO
EBD
ESX
GNUQQ
GROUPED_DOAJ
GUQSH
HCIFZ
HYE
IAO
IHR
ITC
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
OK1
PGMZT
PIMPY
PQQKQ
PROAC
RPM
7TK
7XB
8FK
COVID
MBDVC
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
ID FETCH-LOGICAL-c535t-87bf945bfbe4558e8b36b219634eb4fcb5e6233c8fc9974404daa87ddd37b1a83
IEDL.DBID RPM
ISSN 2076-3425
IngestDate Tue Oct 22 15:14:46 EDT 2024
Tue Sep 17 21:29:41 EDT 2024
Fri Oct 25 05:57:16 EDT 2024
Thu Oct 10 19:12:53 EDT 2024
Fri Feb 23 00:20:43 EST 2024
Fri Feb 02 04:38:11 EST 2024
Fri Aug 23 01:58:37 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Language English
License Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c535t-87bf945bfbe4558e8b36b219634eb4fcb5e6233c8fc9974404daa87ddd37b1a83
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
ORCID 0000-0002-9767-8752
0009-0001-6252-2600
0000-0001-7457-0426
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604956/
PMID 37891860
PQID 2882313854
PQPubID 2032423
ParticipantIDs doaj_primary_oai_doaj_org_article_fa40c7093dc947e29ce9e258e0eeb1cb
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10604956
proquest_miscellaneous_2883576442
proquest_journals_2882313854
gale_infotracmisc_A771912133
gale_infotracacademiconefile_A771912133
crossref_primary_10_3390_brainsci13101494
PublicationCentury 2000
PublicationDate 2023-10-01
PublicationDateYYYYMMDD 2023-10-01
PublicationDate_xml – month: 10
  year: 2023
  text: 2023-10-01
  day: 01
PublicationDecade 2020
PublicationPlace Basel
PublicationPlace_xml – name: Basel
PublicationTitle Brain sciences
PublicationYear 2023
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References ref_50
Sforzini (ref_4) 2022; 27
Fox (ref_71) 2020; 146
ref_12
Veraart (ref_44) 2021; 24
Delfino (ref_52) 2021; 278
ref_55
Maj (ref_40) 2020; 19
ref_53
ref_51
Scala (ref_68) 2023; 38
Floriano (ref_54) 2023; 69
Nogo (ref_48) 2022; 239
Rush (ref_69) 2022; 52
Ng (ref_21) 2021; 293
ref_61
ref_60
Dunn (ref_70) 2023; 61
Chen (ref_16) 2023; 19
ref_25
ref_24
Mkrtchian (ref_47) 2021; 26
ref_22
ref_20
ref_63
ref_62
Zung (ref_33) 1971; 12
Martinotti (ref_11) 2022; 319
ref_28
Hamilton (ref_32) 1959; 32
Zhdanava (ref_1) 2021; 82
Foderaro (ref_26) 2022; 43
Kim (ref_6) 2023; 21
Scott (ref_3) 2023; 37
Moccia (ref_17) 2022; 37
Harris (ref_14) 2020; 77
Gillissie (ref_56) 2023; 158
Benedetti (ref_59) 2022; 37
Cepeda (ref_39) 2018; 35
Paganin (ref_42) 2023; 20
Montgomery (ref_27) 1979; 134
ref_30
Gaynes (ref_23) 2020; 37
Martinotti (ref_5) 2023; 25
(ref_46) 2000; 15
Troubat (ref_57) 2021; 53
Chiappini (ref_10) 2023; 74
Chen (ref_34) 2022; 25
Diekamp (ref_41) 2021; 17
Jawad (ref_13) 2023; 223
Stanghellini (ref_15) 2023; 22
Mauskopf (ref_35) 2009; 26
Almutabagani (ref_65) 2023; 15
Pepe (ref_18) 2023; 29
Roca (ref_37) 2011; 52
ref_45
ref_43
McIntyre (ref_36) 2021; 178
McIntyre (ref_38) 2016; 7
Breeksema (ref_19) 2023; 240
Pettorruso (ref_2) 2023; 327
Miller (ref_58) 2017; 42
Ardalan (ref_7) 2020; 32
ref_9
Santangelo (ref_29) 2009; 15
Popova (ref_8) 2019; 176
Sullivan (ref_31) 1990; 4
Arango (ref_66) 2021; 8
Serretti (ref_49) 2023; 21
Khazanov (ref_67) 2022; 61
Halaris (ref_64) 2023; 1411
References_xml – volume: 12
  start-page: 371
  year: 1971
  ident: ref_33
  article-title: A rating instrument for anxiety disorders
  publication-title: Psychosomatics.
  doi: 10.1016/S0033-3182(71)71479-0
  contributor:
    fullname: Zung
– volume: 26
  start-page: 3292
  year: 2021
  ident: ref_47
  article-title: Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals
  publication-title: Mol. Psychiatry
  doi: 10.1038/s41380-020-00878-1
  contributor:
    fullname: Mkrtchian
– volume: 293
  start-page: 285
  year: 2021
  ident: ref_21
  article-title: Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review
  publication-title: J. Affect. Disord.
  doi: 10.1016/j.jad.2021.06.032
  contributor:
    fullname: Ng
– ident: ref_62
  doi: 10.20944/preprints202306.0108.v1
– volume: 42
  start-page: 2105
  year: 2017
  ident: ref_58
  article-title: The Immunology of Behavior-Exploring the Role of the Immune System in Brain Health and Illness
  publication-title: Neuropsychopharmacology
  doi: 10.1038/npp.2016.229
  contributor:
    fullname: Miller
– volume: 146
  start-page: 1117
  year: 2020
  ident: ref_71
  article-title: Interventions for suicide and self-injury: A meta-analysis of randomized controlled trials across nearly 50 years of research
  publication-title: Psychol. Bull.
  doi: 10.1037/bul0000305
  contributor:
    fullname: Fox
– volume: 69
  start-page: e2023D694
  year: 2023
  ident: ref_54
  article-title: The use of esketamine in the treatment of patients with severe depression and suicidal ideation: Systematic review and meta-analysis
  publication-title: Rev. Assoc. Med. Bras.
  doi: 10.1590/1806-9282.2023d694
  contributor:
    fullname: Floriano
– volume: 74
  start-page: 15
  year: 2023
  ident: ref_10
  article-title: Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study
  publication-title: Eur. Neuropsychopharmacol.
  doi: 10.1016/j.euroneuro.2023.04.011
  contributor:
    fullname: Chiappini
– volume: 24
  start-page: 808
  year: 2021
  ident: ref_44
  article-title: Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review
  publication-title: Int. J. Neuropsychopharmacol.
  doi: 10.1093/ijnp/pyab039
  contributor:
    fullname: Veraart
– ident: ref_50
  doi: 10.1016/j.pnpbp.2021.110289
– volume: 1411
  start-page: 487
  year: 2023
  ident: ref_64
  article-title: The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation?
  publication-title: Adv. Exp. Med. Biol.
  doi: 10.1007/978-981-19-7376-5_21
  contributor:
    fullname: Halaris
– volume: 26
  start-page: 83
  year: 2009
  ident: ref_35
  article-title: Nonresponse, partial response, and failure to achieve remission: Humanistic and cost burden in major depressive disorder
  publication-title: Depress. Anxiety
  doi: 10.1002/da.20505
  contributor:
    fullname: Mauskopf
– volume: 27
  start-page: 1286
  year: 2022
  ident: ref_4
  article-title: A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials
  publication-title: Mol. Psychiatry
  doi: 10.1038/s41380-021-01381-x
  contributor:
    fullname: Sforzini
– volume: 22
  start-page: 352
  year: 2023
  ident: ref_15
  article-title: The lived experience of depression: A bottom-up review co-written by experts by experience and academics
  publication-title: World Psychiatry
  doi: 10.1002/wps.21111
  contributor:
    fullname: Stanghellini
– volume: 25
  start-page: 233
  year: 2023
  ident: ref_5
  article-title: Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression
  publication-title: Bipolar Disord.
  doi: 10.1111/bdi.13296
  contributor:
    fullname: Martinotti
– volume: 20
  start-page: 173
  year: 2023
  ident: ref_42
  article-title: Difficult-To-Treat Depression. Scoping Review
  publication-title: Clin. Neuropsychiatry
  contributor:
    fullname: Paganin
– volume: 319
  start-page: 646
  year: 2022
  ident: ref_11
  article-title: Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study)
  publication-title: J. Affect. Disord.
  doi: 10.1016/j.jad.2022.09.043
  contributor:
    fullname: Martinotti
– volume: 29
  start-page: 325
  year: 2023
  ident: ref_18
  article-title: Reduction in Cognitive Symptoms Following Intranasal Esketamine Administration in Patients with Chronic Treatment-resistant Depression: A 12-Week Case Series
  publication-title: J. Psychiatr. Pract.
  doi: 10.1097/PRA.0000000000000723
  contributor:
    fullname: Pepe
– volume: 134
  start-page: 382
  year: 1979
  ident: ref_27
  article-title: A new depression scale designed to be sensitive to change
  publication-title: Br. J. Psychiatry
  doi: 10.1192/bjp.134.4.382
  contributor:
    fullname: Montgomery
– ident: ref_28
  doi: 10.1037/t00742-000
– volume: 7
  start-page: 153
  year: 2016
  ident: ref_38
  article-title: The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive disorder: Results from the International Mood Disorders Collaborative Project
  publication-title: Ther. Adv. Chronic Dis.
  doi: 10.1177/2040622315627805
  contributor:
    fullname: McIntyre
– ident: ref_55
  doi: 10.1186/s12888-023-05017-y
– volume: 19
  start-page: 587
  year: 2023
  ident: ref_16
  article-title: Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis
  publication-title: Neuropsychiatr. Dis. Treat.
  doi: 10.2147/NDT.S401032
  contributor:
    fullname: Chen
– ident: ref_63
  doi: 10.3390/brainsci13081223
– ident: ref_61
  doi: 10.3390/ph16040634
– ident: ref_51
  doi: 10.1016/j.neubiorev.2022.105000
– volume: 223
  start-page: 109299
  year: 2023
  ident: ref_13
  article-title: The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression
  publication-title: Neuropharmacology
  doi: 10.1016/j.neuropharm.2022.109299
  contributor:
    fullname: Jawad
– volume: 37
  start-page: 79
  year: 2022
  ident: ref_59
  article-title: Antidepressant psychopharmacology: Is inflammation a future target?
  publication-title: Int. Clin. Psychopharmacol.
  doi: 10.1097/YIC.0000000000000403
  contributor:
    fullname: Benedetti
– ident: ref_45
  doi: 10.1186/s12888-023-05038-7
– volume: 15
  start-page: 100
  year: 2023
  ident: ref_65
  article-title: Inflammation and Treatment-Resistant Depression from Clinical to Animal Study: A Possible Link?
  publication-title: Neurol. Int.
  doi: 10.3390/neurolint15010009
  contributor:
    fullname: Almutabagani
– volume: 37
  start-page: 21
  year: 2022
  ident: ref_17
  article-title: Remission of functional motor symptoms following esketamine administration in a patient with treatment-resistant depression: A single-case report
  publication-title: Int. Clin. Psychopharmacol.
  doi: 10.1097/YIC.0000000000000378
  contributor:
    fullname: Moccia
– volume: 38
  start-page: 297
  year: 2023
  ident: ref_68
  article-title: Clinical specificity profile for novel rapid acting antidepressant drugs
  publication-title: Int. Clin. Psychopharmacol.
  doi: 10.1097/YIC.0000000000000488
  contributor:
    fullname: Scala
– volume: 21
  start-page: 429
  year: 2023
  ident: ref_6
  article-title: The Role of Glutamate Underlying Treatment-resistant Depression
  publication-title: Clin. Psychopharmacol. Neurosci.
  doi: 10.9758/cpn.22.1034
  contributor:
    fullname: Kim
– volume: 25
  start-page: 269
  year: 2022
  ident: ref_34
  article-title: Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression
  publication-title: Int. J. Neuropsychopharmacol.
  doi: 10.1093/ijnp/pyab084
  contributor:
    fullname: Chen
– volume: 82
  start-page: 20m13699
  year: 2021
  ident: ref_1
  article-title: The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States
  publication-title: J. Clin. Psychiatry
  doi: 10.4088/JCP.20m13699
  contributor:
    fullname: Zhdanava
– volume: 178
  start-page: 383
  year: 2021
  ident: ref_36
  article-title: Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation
  publication-title: Am. J. Psychiatry
  doi: 10.1176/appi.ajp.2020.20081251
  contributor:
    fullname: McIntyre
– volume: 19
  start-page: 269
  year: 2020
  ident: ref_40
  article-title: The clinical characterization of the adult patient with depression aimed at personalization of management
  publication-title: World Psychiatry
  doi: 10.1002/wps.20771
  contributor:
    fullname: Maj
– ident: ref_53
– ident: ref_30
– volume: 52
  start-page: 26
  year: 2011
  ident: ref_37
  article-title: Clinical differences between first and recurrent episodes in depressive patients
  publication-title: Compr. Psychiatry
  doi: 10.1016/j.comppsych.2010.04.011
  contributor:
    fullname: Roca
– volume: 158
  start-page: 209
  year: 2023
  ident: ref_56
  article-title: Evaluating Anhedonia as a risk factor in suicidality: A meta-analysis
  publication-title: J. Psychiatr. Res.
  doi: 10.1016/j.jpsychires.2022.12.024
  contributor:
    fullname: Gillissie
– ident: ref_24
– volume: 61
  start-page: 255
  year: 2022
  ident: ref_67
  article-title: Addressing anhedonia to increase depression treatment engagement
  publication-title: Br. J. Clin. Psychol.
  doi: 10.1111/bjc.12335
  contributor:
    fullname: Khazanov
– ident: ref_22
  doi: 10.1176/appi.books.9780890425787
– volume: 15
  start-page: 576
  year: 2009
  ident: ref_29
  article-title: Anhedonia and cognitive impairment in Parkinson’s disease: Italian validation of the Snaith-Hamilton Pleasure Scale and its application in the clinical routine practice during the PRIAMO study
  publication-title: Park. Relat. Disord.
  doi: 10.1016/j.parkreldis.2009.02.004
  contributor:
    fullname: Santangelo
– volume: 17
  start-page: 2347
  year: 2021
  ident: ref_41
  article-title: Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials
  publication-title: Neuropsychiatr. Dis. Treat.
  doi: 10.2147/NDT.S314874
  contributor:
    fullname: Diekamp
– volume: 15
  start-page: 160
  year: 2000
  ident: ref_46
  article-title: Rating depressed patients: Observer- vs self-assessment
  publication-title: Eur. Psychiatry
  doi: 10.1016/S0924-9338(00)00229-7
– volume: 37
  start-page: 134
  year: 2020
  ident: ref_23
  article-title: Defining treatment-resistant depression
  publication-title: Depress. Anxiety
  doi: 10.1002/da.22968
  contributor:
    fullname: Gaynes
– volume: 43
  start-page: 3053
  year: 2022
  ident: ref_26
  article-title: Brand new norms for a good old test: Northern Italy normative study of MiniMental State Examination
  publication-title: Neurol. Sci.
  doi: 10.1007/s10072-021-05845-4
  contributor:
    fullname: Foderaro
– volume: 32
  start-page: 50
  year: 1959
  ident: ref_32
  article-title: The assessment of anxiety states by rating
  publication-title: Br. J. Med. Psychol.
  doi: 10.1111/j.2044-8341.1959.tb00467.x
  contributor:
    fullname: Hamilton
– volume: 35
  start-page: 668
  year: 2018
  ident: ref_39
  article-title: Finding factors that predict treatment-resistant depression: Results of a cohort study
  publication-title: Depress. Anxiety
  doi: 10.1002/da.22774
  contributor:
    fullname: Cepeda
– ident: ref_12
  doi: 10.1007/s00406-023-01617-7
– ident: ref_43
  doi: 10.3390/ijms22179338
– volume: 327
  start-page: 115378
  year: 2023
  ident: ref_2
  article-title: Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING)
  publication-title: Psychiatry Res.
  doi: 10.1016/j.psychres.2023.115378
  contributor:
    fullname: Pettorruso
– volume: 61
  start-page: 102084
  year: 2023
  ident: ref_70
  article-title: Preliminary clinical and cost effectiveness of augmented depression therapy versus cognitive behavioural therapy for the treatment of anhedonic depression (ADepT): A single-centre, open-label, parallel-group, pilot, randomised, controlled trial
  publication-title: eClinicalMedicine
  doi: 10.1016/j.eclinm.2023.102084
  contributor:
    fullname: Dunn
– volume: 8
  start-page: 14
  year: 2021
  ident: ref_66
  article-title: Reconceptualising treatment-resistant depression as difficult-to-treat depression
  publication-title: Lancet Psychiatry
  doi: 10.1016/S2215-0366(20)30516-2
  contributor:
    fullname: Arango
– volume: 240
  start-page: 1547
  year: 2023
  ident: ref_19
  article-title: Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: An interpretative phenomenological study
  publication-title: Psychopharmacology
  doi: 10.1007/s00213-023-06388-6
  contributor:
    fullname: Breeksema
– volume: 4
  start-page: 99
  year: 1990
  ident: ref_31
  article-title: A survey of multiple sclerosis, part 1: Perceived cognitive problems and compensatory strategy use
  publication-title: Can. J. Rehabil.
  contributor:
    fullname: Sullivan
– ident: ref_9
  doi: 10.1016/j.jagp.2023.06.016
– ident: ref_25
– volume: 53
  start-page: 151
  year: 2021
  ident: ref_57
  article-title: Neuroinflammation and depression: A review
  publication-title: Eur. J. Neurosci.
  doi: 10.1111/ejn.14720
  contributor:
    fullname: Troubat
– volume: 52
  start-page: 419
  year: 2022
  ident: ref_69
  article-title: Clinical research challenges posed by difficult-to-treat depression
  publication-title: Psychol. Med.
  doi: 10.1017/S0033291721004943
  contributor:
    fullname: Rush
– volume: 239
  start-page: 2011
  year: 2022
  ident: ref_48
  article-title: The effect of ketamine on anhedonia: Improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits
  publication-title: Psychopharmacology
  doi: 10.1007/s00213-022-06105-9
  contributor:
    fullname: Nogo
– ident: ref_60
  doi: 10.1016/j.neubiorev.2023.105307
– volume: 21
  start-page: 401
  year: 2023
  ident: ref_49
  article-title: Anhedonia and Depressive Disorders
  publication-title: Clin. Psychopharmacol. Neurosci.
  doi: 10.9758/cpn.23.1086
  contributor:
    fullname: Serretti
– volume: 37
  start-page: 268
  year: 2023
  ident: ref_3
  article-title: Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression
  publication-title: J. Psychopharmacol.
  doi: 10.1177/02698811221104058
  contributor:
    fullname: Scott
– volume: 278
  start-page: 515
  year: 2021
  ident: ref_52
  article-title: Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression
  publication-title: J. Affect. Disord.
  doi: 10.1016/j.jad.2020.09.056
  contributor:
    fullname: Delfino
– ident: ref_20
  doi: 10.1007/s11136-023-03451-9
– volume: 77
  start-page: 830
  year: 2020
  ident: ref_14
  article-title: Findings from World Mental Health Surveys of the Perceived Helpfulness of Treatment for Patients with Major Depressive Disorder
  publication-title: JAMA Psychiatry
  doi: 10.1001/jamapsychiatry.2020.1107
  contributor:
    fullname: Harris
– volume: 32
  start-page: 94
  year: 2020
  ident: ref_7
  article-title: Rapid effects of S-ketamine on the morphology of hippocampal astrocytes and BDNF serum levels in a sex-dependent manner
  publication-title: Eur. Neuropsychopharmacol.
  doi: 10.1016/j.euroneuro.2020.01.001
  contributor:
    fullname: Ardalan
– volume: 176
  start-page: 428
  year: 2019
  ident: ref_8
  article-title: Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined with a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study
  publication-title: Am. J. Psychiatry
  doi: 10.1176/appi.ajp.2019.19020172
  contributor:
    fullname: Popova
SSID ssj0000800350
Score 2.3144917
Snippet The effectiveness of the esketamine nasal spray (ESK-NS) for treatment-resistant depression (TRD) has been confirmed by real-world studies. Available evidence...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
StartPage 1494
SubjectTerms Antidepressants
Cognition
Cognition & reasoning
Depression, Mental
Drug therapy
glutamatergic system
Hedonic response
Mental depression
mood disorders
patient experience
Patients
personalized medicine
Phenotypes
Psychopathology
psychopharmacology
Respiratory agents
Suicide
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQT1wQUBCBUrkSAnGImtjjdXxcoFVBAlWolXqzYmcsCqoXkfTAjdfg9XiSjp1suykHLlxjJ3Hmx54vHn_D2AtaE-qubU0ZEBYl1FqXrdCuTEzhWjivTa6x9PHT4ugUPpyps41SXyknbKQHHgW3H1qovCbc3XkDGoXxaFCoBiukaca7PPtWZgNMfZ3iIKmqcV9SEq7fd6niAq0qtUzVaQ3M1qFM1__3pHw7UXJj5Tm8z-5NISNfjkN9wO5gfMi2l5Hg8sVP_pLnJM78d3ybIamdH49cqX9-_e758c1hSr6KnMI9PhIW93wV-Pv0wtj29PiD_hsO7QUFnfw88pN1_nn5GfsUYsaBv1snzcZH7PTw4OTtUTlVUii9kmqgKc8FA8oFh6BIdo2TCyeS8wE6CN4ppDBI-iZ4YzJlIOmv0V3XSe3qtpGP2VZcRXzCuAs6oJRAUEMAeuOqAFVQugLQcoFQsNdrudrvI2GGJaCRdGBv66Bgb5Lgr_slqut8gQzATgZg_2UABXuV1GaTQ5LMfDudK6DhJmoru9SaMKkgLF6wnVlPciQ_b14r3k6O3FvRpH1S2Sga7N51c7ozJadFXF3mPpJgG4AoWDMzmNmXzVvi-ZdM5l0n9iICqU__hyyesbuCgrAx2XCHbQ0_LvE5BU2D283-cQUKyBnU
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwELZge-GCgIIIFGQkBOIQNWuP1_EJbWGrgkS1qlqptyh2bFqhOqVJD9x4DV6PJ2EmP1tSJK6xE8cej2c-e_wNY6_RJsyrsjRp8LBIYa51WgptU2IK18I6bbocS18OFwcn8PlUnQ4bbs0QVjmuid1CXdWO9sh3RU4HVjJX8P7ye0pZo-h0dUihcZdtCUQK2Yxt7a0O10ebXRbyh6TK-vNJifh-11LmBbQuc0lZag1M7FFH2__v4nw7YPIvC7T_gN0fXEe-7GX9kN3x8RHbXkaEzRc_-BveBXN2u-TbzKP4-brnTP3981fD1zeXKnkdObp9vCcubngd-CdqMJYNfn7VfPNteYHOJz-P_HiMQ0-PfEOuZmz5xzF4Nj5mJ_ur4w8H6ZBRIXVKqhaXPhsMKBusB6Vyn1u5sIKUELyF4Kzy6A5JlwdnTEcdiHLMdVVVUtt5mcsnbBbr6J8yboMOXkpAyCHAO2OzAFlQOgPQcuEhYe_GcS0ue-KMAgEHyaC4LYOE7dHAb-oR5XX3oL76WgwaVIQSMqczIytnQHthnDdeYCcyj_bG2YS9JbEVpJg4Zq4c7hfg7xLFVbHUGrGpQEyesJ1JTVQoNy0eBV8MCt0UN9MvYa82xfQmBalFX193dSTCNwCRsHwyYSY9m5bE87OO1HtOLEYIVp_9v_Xn7B4lvO_DCXfYrL269i_QLWrty2Hu_wFtRBFs
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NbtQwELagXLggoCCWFmQkBOIQSOzJOj4gtECrggSqUFfqLYqdcSm0DmxSid54DV6PJ2HsJC0pvXCNnR_PT2a-ZPwNY48pJmR1VenEIcwTyJRKKqFMEpjClTBW6dhj6cPH-c4S3u_n--fbowcBtpdCu9BPark6ev7j--krcviXAXESZH9hQjMFChiZDI1nNVxl1wQQTg-FfEOy_2XIjWRs2SoIvCeSrLX_b3npRSZxKtL5__vSvlhI-Vdk2r7JbgwpJV_0NnCLXUF_m60vPMHp41P-hMciz_j1fJ0hmQXf7blUf__81fLd882WvPGc0kHeExq3vHH8Xbihr1q6_Fb7FbvqmJJSfuj53lifnnzCNqSgvuNvx6Jaf4ctt7f23uwkQ6eFxOYy7-iVaJyG3DiDkOcFFkbOjQjOCWjAWZMjpUnSFs5qHSkFSb-FqutaKpNVhbzL1nzj8R7jximHUgJBEQFotUkdpC5XKYCSc4QZezbKtfzWE2qUBESCDsqLOpix10HwZ_MCFXY80KwOysGzSldBalWqZW01KBTaokZBi0iR4pA1M_Y0qK0MJkQys9Ww74AeN1BflQulCLMKwuoztjmZSY5mp8Oj4svRTktRhP-ossjpYR-dDYczQ_Gax-YkzpEE6wDEjBUTg5msbDriDz9Hsu8ssBsRiL3_H3LbYNcF5WJ9zeEmW-tWJ_iAcqfOPIwu8QdIeRp1
  priority: 102
  providerName: Scholars Portal
Title The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
URI https://www.proquest.com/docview/2882313854
https://search.proquest.com/docview/2883576442
https://pubmed.ncbi.nlm.nih.gov/PMC10604956
https://doaj.org/article/fa40c7093dc947e29ce9e258e0eeb1cb
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Bb9MwFLa2ceGCBgNRNiojIRCHrElsx_ax6zptSB3VtKHdotixoUCdackO3Pgb_D1-Cc9Osi3jxqWVaqdx_Pzyvpd8_h5CbyEmJGVRyMgamkU04TwqUq4irxTOU6W5DDWWFqfZ8QX9eMkuN1DW74UJpH2tVvvux3rfrb4GbuXVWk96nthkuZglXvEFgP1kE23CCr2Xo3_rMBBhcftOkkBOP1G-2gJElIT4yrTS1-IhXMhEBGHKu3AUVPv_vTc_5EveC0BH2-hJhxzxtB3hU7Rh3DO0M3WQNa9_4nc4cDnDQ_IdZMD6eNlKpv759bvGy7s9lbhyGFAfbnWLa1xZfOJP6Ioa_n5efzdNsQbsiVcOn_c09OjM1B5pugYf9txZ9xxdHM3PZ8dRV1Ah0oywBu58ykrKlFWGMiaMUCRTqfdBahS1WjEDaIhoYbWUQTkQzCh4WZaEq6QQ5AXacpUzLxFWlltDCIWMI6VGSxVbGlvGY0o5yQwdoQ_9vOZXrW5GDvmGN0f-0BwjdOAn_rafV7wOP1TXX_LO7rktaKx5LEmpJeUmldpIk8JFxAbCjVYj9N6bLfd-CXOmi257AQzXK1zlU84hNU0hJR-hvUFP8Cc9bO4Nn3f-XOep8K9LiWAw2De3zf5Iz1FzproJfQhkb5SmIyQGC2ZwZcMWWOJB07tf0q_-_9Bd9DgFBNYyDffQVnN9Y14DYmrUGD06mJ8uz-B79unzyeE4PHmAzwUV4-A8fwF_4h5s
link.rule.ids 230,315,730,783,787,867,888,2109,2228,21400,24330,27936,27937,33756,33757,38528,43817,43907,53804,53806,74630,74740
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwELagPcClAgoiUMBICMQhauKfdXxCW9hqC-1qVW2l3qLYsaFCddomPXDjNXg9noSZ_GxJkbjGThx7PJ757PE3hLwBm5CWRaFj78QkFqlSccGUiZEpXDFjlW5zLB0tJvMT8flUnvYbbnUfVjmsie1CXVYW98h3WYYHVjyT4sPFZYxZo_B0tU-hcZdsIlUVgK_NvdliebzeZUF_iMukO5_kgO93DWZeAOuScsxSq8XIHrW0_f8uzrcDJv-yQPsPyFbvOtJpJ-uH5I4Lj8j2NABsPv9B39I2mLPdJd8mDsRPlx1n6u-fv2q6vLlUSatAwe2jHXFxTStPD7DBUNTw-Vn93TXFOTif9CzQ1RCHHh-7Gl3N0NBPQ_BseExO9merj_O4z6gQW8llA0uf8VpI440TUmYuM3xiGCqhcEZ4a6QDd4jbzFutW-pAkGOmyrLkyqRFxp-QjVAF95RQ45V3nAuAHEw4q03iReKlSoRQfOJERN4P45pfdMQZOQAOlEF-WwYR2cOBX9dDyuv2QXX1Ne81KPeFSKxKNC-tFsoxbZ12DDqROLA31kTkHYotR8WEMbNFf78AfhcprvKpUoBNGWDyiOyMaoJC2XHxIPi8V-g6v5l-EXm9LsY3MUgtuOq6rcMBvgnBIpKNJsyoZ-OScPatJfVOkcUIwOqz_7f-itybr44O88ODxZfn5D4Dl6sLLdwhG83VtXsBLlJjXvZ68AePKBRm
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwELZgKyEuCCiIQAEjIRCHaBP_rOMT2tJdtfysVlUr9WbFjl0qVKc06YEbr8Hr8SSME2dLisQ1duLY4_HM2J-_Qeg12IS8KkuZOstmKcuFSEsidBqYwgXRRsgux9KX1Wz_mH084ScR_9REWOWwJnYLdVWbsEc-JUU4sKIFZ1MXYRHrveX7i-9pyCAVTlpjOo3baEuwGc0maGt3sVofbnZcgm9EedafVVKI9ac6ZGEAS5PTkLFWspFt6ij8_12ob4In_7JGy_voXnQj8byX-wN0y_qHaHvuIYQ-_4Hf4A7Y2e2YbyMLUwGve_7U3z9_NXh9fcES1x6DC4h7EuMG1w4fhAZ92cDnF80325bn4IjiM4-PBkx6emib4Hb6Fu8NQFr_CB0vF0cf9tOYXSE1nPIWlkHtJOPaacs4L2yh6UyToJDMauaM5hZcI2oKZ6TsaARBpoWoqooKnZcFfYwmvvb2CcLaCWcpZRB-EGaN1JljmeMiY0zQmWUJejeMq7roSTQUBB9BBuqmDBK0GwZ-Uy_QX3cP6stTFbVJuZJlRmSSVkYyYYk0VloCncgs2B6jE_Q2iE0FJYUxM2W8awC_G-iu1FwIiFMJxOcJ2hnVBOUy4-JB8Coqd6Oup2KCXm2Kw5sBsOZtfdXVoRDKMUYSVIwmzKhn4xJ_9rUj-M4DoxEErk__3_pLdAdUQH0-WH16hu4S8L56lOEOmrSXV_Y5eEutfhHV4A81XBiU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Patient%E2%80%99s+Perspective+on+the+Effects+of+Intranasal+Esketamine+in+Treatment-Resistant+Depression&rft.jtitle=Brain+sciences&rft.au=Pepe%2C+Maria&rft.au=Bartolucci%2C+Giovanni&rft.au=Marcelli%2C+Ilaria&rft.au=Pesaresi%2C+Francesco&rft.date=2023-10-01&rft.issn=2076-3425&rft.eissn=2076-3425&rft.volume=13&rft.issue=10&rft.spage=1494&rft_id=info:doi/10.3390%2Fbrainsci13101494&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_brainsci13101494
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2076-3425&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2076-3425&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2076-3425&client=summon